Sirolimus as Primary Therapy for the Treatment of Chronic Graft Versus Host Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00186667|
Recruitment Status : Completed
First Posted : September 16, 2005
Last Update Posted : July 27, 2010
|Condition or disease||Intervention/treatment||Phase|
|Graft vs Host Disease Blood and Marrow Transplant (BMT)||Procedure: high dose chemotherapy and autologous hematopoietic cell transplant||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Open Label Study of Sirolimus as Primary Therapy for the Treatment of Chronic GVHD Following Allogeneic Bone Marrow Transplant|
|Study Start Date :||January 1999|
|Actual Primary Completion Date :||January 2000|
|Actual Study Completion Date :||September 2005|
- Evaluate the efficacy of clinical activity of sirolimus in combination with cyclosporine and corticosteroids as first line therapy for the treatment of chronic Graft Versus Host Disease.
- Evaluate the safety of clinical activity of sirolimus in combination with cyclosporine and corticosteroids as first line therapy for the treatment of chronic Graft Versus Host Disease.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00186667
|United States, California|
|Stanford University School of Medicine|
|Stanford, California, United States, 94305|
|Principal Investigator:||Laura Johnston||Stanford University|